サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1544084

デング熱ワクチンの世界市場

Dengue Vaccine

出版日
ページ情報
英文 193 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
デング熱ワクチンの世界市場
出版日: 2024年08月29日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

デング熱ワクチンの世界市場は2030年までに16億米ドルに達する見込み

2023年に5億8,900万米ドルと推定されるデング熱ワクチンの世界市場は、2023年から2030年にかけてCAGR 15.8%で成長し、2030年には16億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである政府機関の最終用途は、CAGR 14.2%を記録し、分析期間終了時には7億7,460万米ドルに達すると予測されます。病院の最終用途セグメントの成長率は、分析期間中CAGR 16.6%と推定されます。

米国市場は1億5,190万米ドルと推定、中国はCAGR 20.1％で成長すると予測

米国のデング熱ワクチン市場は、2023年に1億5,190万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR 20.1％を追いかけ、2030年までに4億1,280万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.2%と13.2%と予測されています。欧州では、ドイツがCAGR約12.2%で成長すると予測されています。

世界のデング熱ワクチン市場- 主要動向と促進要因のまとめ

デング熱ワクチンとは何か？

デング熱ワクチンは、CYD-TDVまたは商品名Dengvaxiaとしても知られ、デングウイルスによって引き起こされるデング熱の予防のために承認された最初のワクチンです。デング熱は蚊によって媒介され、世界中の熱帯・亜熱帯気候で流行しており、毎年数百万人がインフルエンザのような重篤な症状や生命を脅かす可能性のある合併症に罹患しています。このワクチンは、デングウイルス蛋白質を発現させるベクターとして黄熱ウイルスの弱毒化版を利用し、4つのウイルス血清型すべてに反応する組換え4価生ワクチンです。これによって免疫系が刺激され、デングウイルスが人体に侵入した場合に、デングウイルスに特異的に標的を定めた防御機構を産生します。しかし、このワクチンは血清陽性の集団、つまり過去にウイルスに感染したことのある集団にのみ使用が推奨されています。血清陰性の集団、つまりウイルスにさらされたことのない集団では、重症デング熱のリスクが高まる可能性があるからです。

デング熱ワクチンの臨床的知見と公衆衛生上の利点とは？

デング熱ワクチンの臨床試験では、血清型や年齢層によって有効性にばらつきがあることが示されており、全体的な有効性は60％前後です。ワクチンの有効性は、過去にデング熱に感染したことのある人において顕著に高く、このような感染が多い流行地域での有用性が強調されています。このワクチンの公衆衛生上の利点には、入院率の減少や重症デング熱患者の減少などがあり、感染地域のヘルスケアシステムの負担を軽減する上で重要です。そのため、このワクチンは、特にデング熱の流行が高い地域において、デング熱との闘いにおける重要な手段であると考えられています。デング熱の発生を減らすことで、命を救うだけでなく、ヘルスケアコストや病気による生産性の低下に関連する経済的損失も減らすことができます。

デング熱ワクチンの展開における課題と留意点は？

デング熱ワクチンの展開には、いくつかの課題と倫理的配慮が必要です。特にデングウイルスに感染したことのある人を特定することです。これには信頼性の高い血清学的検査が必要だが、資源に乏しい環境ではコストがかかり、論理的にも難しいです。また、血清反応が陰性であるワクチン接種者がワクチンに関連して重症デング熱を発症するリスクもあり、一部の地域では初期展開後に論争や社会的不信につながりました。このような課題から、ワクチン接種に伴う利益を最大化し、リスクを最小化するために、慎重な計画と広報戦略が必要です。さらに、長期的なワクチンの安全性と有効性を監視するためには、継続的な調査とサーベイランスが不可欠となります。

デング熱ワクチン市場の成長を促進する要因は？

デング熱ワクチン市場の成長の原動力となる要因はいくつかありますが、主に100カ国以上で高い疾病負担が発生しており、効果的な予防対策への需要が高まっていることが挙げられます。また、地球温暖化による流行地域の拡大や、蚊にとって理想的な繁殖条件を作り出す都市化の進展も、ワクチンの必要性に拍車をかけています。さらに、海外旅行の増加によりデング熱が新たな地域に持ち込まれ続けており、世界の関心とワクチン接種の需要が高まっています。ワクチン技術の進歩とデング熱研究への資金提供の増加により、デング熱ワクチンの開発と改良が加速し、より入手しやすく手頃な価格になっています。官民パートナーシップや、総合的なデング熱予防計画の一環としてワクチン接種を推進する世界保健機関（WHO）のような世界保健機関によるイニシアチブも、市場の成長に寄与しています。こうした要因に加え、デング熱の影響に対する意識の高まりや予防オプションの利用が可能になったことで、デング熱ワクチン市場はダイナミックに拡大しています。

調査対象企業の例（注目の44社）

  • Biological E. Ltd.
  • GlaxoSmithKline plc
  • Instituto Butantan
  • Panacea Biotec Ltd.
  • Sanofi SA
  • Takeda Pharmaceuticals Company Ltd.
  • Vabiotech

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP11492

Global Dengue Vaccine Market to Reach US$1.6 Billion by 2030

The global market for Dengue Vaccine estimated at US$589.0 Million in the year 2023, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 15.8% over the analysis period 2023-2030. Government Institutions End-Use, one of the segments analyzed in the report, is expected to record a 14.2% CAGR and reach US$774.6 Million by the end of the analysis period. Growth in the Hospitals End-Use segment is estimated at 16.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$151.9 Million While China is Forecast to Grow at 20.1% CAGR

The Dengue Vaccine market in the U.S. is estimated at US$151.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$412.8 Million by the year 2030 trailing a CAGR of 20.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.2% and 13.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

Global Dengue Vaccine Market - Key Trends and Drivers Summarized

What Is the Dengue Vaccine and How Does It Work Against the Virus?

The dengue vaccine, also known as CYD-TDV or by its commercial name Dengvaxia, is the first vaccine approved for the prevention of dengue disease, caused by the dengue virus. Dengue is transmitted by mosquitoes and is prevalent in tropical and subtropical climates worldwide, affecting millions annually with severe flu-like symptoms and potentially life-threatening complications. The vaccine is a live recombinant tetravalent response to all four virus serotypes, utilizing a weakened version of the yellow fever virus as a vector to express dengue virus proteins. This stimulates the immune system to produce a defense mechanism specifically targeted against the dengue virus if it enters the human body. However, its use is recommended only in populations that are seropositive, meaning they have been previously infected by the virus, as the vaccine can increase the risk of severe dengue in seronegative individuals, those who have never been exposed to the virus.

What Are the Clinical Insights and Public Health Benefits of the Dengue Vaccine?

Clinical trials for the dengue vaccine have shown varied efficacy rates across different serotypes and age groups, with overall efficacy hovering around 60%. The vaccine's effectiveness is notably higher in individuals who have had a previous dengue infection, underscoring its utility in endemic regions where such exposure is common. Public health benefits of the vaccine include reduced hospitalization rates and a decrease in severe dengue cases, which are significant in helping ease the burden on healthcare systems in affected regions. The vaccine is thus considered a critical tool in the fight against dengue, particularly in high-prevalence areas. By reducing the incidence of dengue, it not only saves lives but also reduces economic loss related to healthcare costs and lost productivity due to illness.

What Are the Challenges and Considerations in the Deployment of the Dengue Vaccine?

The deployment of the dengue vaccine has faced several challenges and ethical considerations. One major issue is determining vaccine eligibility, particularly in identifying individuals previously infected by the dengue virus. This requires reliable serological testing, which can be costly and logistically challenging in resource-poor settings. There's also the risk of vaccine-related severe dengue in seronegative vaccine recipients, which has led to controversies and public distrust in some regions following early roll-outs. These challenges necessitate careful planning and public communication strategies to maximize benefits and minimize risks associated with vaccination. Additionally, ongoing research and surveillance are crucial to monitor long-term vaccine safety and effectiveness, especially as the virus evolves and different population dynamics come into play.

What Drives the Growth in the Dengue Vaccine Market?

The growth in the dengue vaccine market is driven by several factors, primarily the high burden of disease in over 100 countries, increasing the demand for effective preventive measures. The expansion of endemic areas due to global warming and increased urbanization, which create ideal breeding conditions for mosquitoes, also spur the need for vaccines. Furthermore, growing international travel continues to introduce dengue into new regions, raising global concern and demand for vaccination. Advances in vaccine technology and increased funding for dengue research have accelerated the development and improvement of dengue vaccines, making them more accessible and affordable. Public-private partnerships and initiatives by global health bodies like the World Health Organization (WHO) to promote vaccination as part of integrated dengue prevention plans also contribute to the growth of the market. These factors, combined with a heightened awareness of the impact of dengue and the availability of preventive options, ensure a dynamic and expanding market for the dengue vaccine.

Select Competitors (Total 44 Featured) -

  • Biological E. Ltd.
  • GlaxoSmithKline plc
  • Instituto Butantan
  • Panacea Biotec Ltd.
  • Sanofi SA
  • Takeda Pharmaceuticals Company Ltd.
  • Vabiotech

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Dengue Vaccine - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Dengue Fever Drives Urgency for Vaccine Development
    • Increasing Government and NGO Funding Propels Dengue Vaccine Research and Trials
    • Expansion of Vaccine Coverage in Endemic Regions Enhances Market Opportunities
    • Growing Public Health Initiatives Support Dengue Vaccination Programs
    • Integration of Dengue Vaccination in National Immunization Programs
    • Rising Travel and Migration Patterns Increase Demand for Dengue Vaccination
    • Growing Awareness Campaigns Enhance Public Acceptance of Dengue Vaccination
    • Growing Pediatric Population in Dengue-Prevalent Regions Drives Market Demand
    • Emergence of Vaccine Tourism in Dengue Endemic Regions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Dengue Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Government Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Government Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Government Institutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for NGOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Dengue Vaccine Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • JAPAN
    • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • CHINA
    • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • EUROPE
    • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Dengue Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • FRANCE
    • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • GERMANY
    • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Dengue Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • INDIA
    • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Dengue Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Dengue Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
  • AFRICA
    • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030

IV. COMPETITION